Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4771
AIMD
Ainos, Inc. - Common Stock
1.42 USD0.00%-3.40%+9.23%-64.85%10.49 M USD
4782
SINT
SiNtx Technologies, Inc. - Common Stock
1.53 USD-3.16%-0.65%-3.16%-50.65%10.20 M USD
4834
CODX
Co-Diagnostics, Inc. - Common Stock
1.26 USD+0.80%+6.78%-14.29%-60.63%7.88 M USD
4835
NVNO
enVVeno Medical Corporation - Common Stock
11.47 USD0.00%+7.80%+8.21%+1203.41%7.83 M USD

Frequently asked questions about 20/20 Biolabs, Inc. Common Stock

What is the 20/20 Biolabs, Inc. Common Stock stock price today?

The current price of 20/20 Biolabs, Inc. Common Stock (AIDX) is 0.62. Over the past 24 hours, the stock has changed by +10.71%. Follow the AIDX chart for real-time price dynamics.

What is the stock ticker of 20/20 Biolabs, Inc. Common Stock?

20/20 Biolabs, Inc. Common Stock trades under the ticker AIDX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is 20/20 Biolabs, Inc. Common Stock stock going up?

AIDX has changed by +19.23% over the last week, +40.91% over the last month, and -98.76% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of 20/20 Biolabs, Inc. Common Stock?

20/20 Biolabs, Inc. Common Stock currently has a market capitalization of 7.92 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were 20/20 Biolabs, Inc. Common Stock earnings last quarter?

Last quarter, 20/20 Biolabs, Inc. Common Stock reported earnings of -0.26 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was 20/20 Biolabs, Inc. Common Stock revenue for the last quarter?

20/20 Biolabs, Inc. Common Stock reported quarterly revenue of 730.57 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was 20/20 Biolabs, Inc. Common Stock net income for the last quarter?

20/20 Biolabs, Inc. Common Stock reported net income of -1.51 M for the last quarter. The previous quarter showed -2.17 M, which means net income changed by +30.74%.

How many employees does 20/20 Biolabs, Inc. Common Stock have?

As of the latest available data, 20/20 Biolabs, Inc. Common Stock has 14 employees. Workforce size can provide additional context about the company's scale and operations.

What is 20/20 Biolabs, Inc. Common Stock EBITDA?

20/20 Biolabs, Inc. Common Stock EBITDA is -1.23 M, and its EBITDA margin is -168.62%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy 20/20 Biolabs, Inc. Common Stock stock?

You can buy 20/20 Biolabs, Inc. Common Stock (AIDX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in 20/20 Biolabs, Inc. Common Stock stock?

Investing in 20/20 Biolabs, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AIDX chart and related analysis on metatrader.com as part of your research.